# The Branded Health Service Medicines (Costs) Regulations 2018, Regulation 22: Presentation report

Extent: E+W+S+N.I.

Where a manufacturer or supplier is required to provide the Secretary of State with a “presentation report” by these Regulations, the presentation report must be provided via the relevant NHS BSA online gateway and, with respect to each presentation, separately set out—
(a) the name of each presentation supplied and whether it is a newer presentation or an older presentation;
(b) except in relation to the supply of items of presentation specified in regulation 3(4)(a), (b), (c), (d), (g) and (h), the quantity of each presentation supplied to—
(i) wholesalers,
(ii) primary medical services providers,
(iii) NHS chemists,
(iv) relevant UK hospitals, and
(v) any other persons or bodies;
(c) except in relation to the supply of items of presentations specified in regulation 3(4)(a), (b), (c), (d), (g) and (h), the total gross sales income and total net sales income received for the supply of each presentation to each of the categories listed in paragraph (b);
(d) with respect to a contract with a contracting authority based on a framework agreement under which the item of presentation supplied is excluded from the calculation of net sales income in accordance with regulation 3(4)(a)(i), details of the contract with the contracting authority, the framework agreement on which that contract is based and the item of presentation so supplied;
(e) with respect to a public contract under which the item of presentation supplied is excluded from the calculation of net sales income in accordance with regulation 3(4)(a)(ii), details of the public contract and the item of presentation so supplied;
(f) the quantity supplied and the total gross sales income and total net sales income received for the supply of—
(i) each presentation which was supplied under a contract with a contracting authority based on a framework agreement, where the framework agreement was entered into on or before the date of coming into force of these Regulations or was entered into following a tender which closed on or before the date of coming into force of these Regulations, and
(ii) each presentation which was supplied under a public contract entered into before the date of the coming into force of these Regulations or was entered into following a tender which closed on or before the date of the coming into force of these Regulations;
(fa) with respect to the net sales income received in respect of the supply of an item of presentation under a contract with a contracting authority based on a framework agreement to which a payment percentage is determined in accordance with regulation 3(5A), details of the contract with the contracting authority, the framework agreement on which that contract is based and the item of presentation so supplied;
(fb) with respect to the net sales income received in respect of the supply of an item of presentation under a public contract to which a payment percentage is determined in accordance with regulation 3(5A), details of the public contract and the item of presentation so supplied;
(fc) the quantity supplied and the total gross sales income and total net sales income received in respect of the supply of—
(i) each presentation which was supplied under a contract with a contracting authority based on a framework agreement, where the framework agreement was entered into on or after 1st April 2018 but before 1st January 2019 or was entered into following a tender which closed on or after 1st April 2018 but before 1st January 2019, and
(ii) each presentation which was supplied under a public contract entered into on or after 1st April 2018 but before 1st January 2019, or was entered into following a tender which closed on or after 1st April 2018 but before 1st January 2019;
(g) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each low cost presentation;
(ga) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of new active substance presentation supplied;
(gb) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item which is a line extension to which regulation 3(4)(f) applies that is supplied;
(gc) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of exceptional central procurement presentation supplied;
(gd) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of centrally procured vaccine presentation supplied;
(ge) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of presentation of plasma derived medicinal products;
(gf) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of presentation to which regulation 3(4A)(b) applies that is supplied;
(h) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each parallel distributed presentation;
(i) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each voluntary scheme presentation; and
(j) for the purposes of paragraph (i), information which verifies that the relevant presentation is a voluntary scheme presentation.

---
Source: https://www.legislation.gov.uk/uksi/2018/345/regulation/22 (the official version)
Page: https://openlegislation.uk/branded-health-service-medicines-costs-regulations-2018/regulation-22
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.